Compare Godaddy Inc (GDDY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Novo Nordisk A/S — how do they compare? Godaddy Inc trades at $93.92 (market cap $12.09B), while Novo Nordisk A/S trades at $51.6 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 18.4× Godaddy Inc's market cap, and Novo Nordisk A/S pays a 3.56% dividend while Godaddy Inc pays none. Which is the better fit depends on your goals.
| GDDY | NVO | |
|---|---|---|
Market Cap | $12.09B | $222.24B |
Sector | Technology | Health |
52-Week High | $169.40 | $71.70 |
52-Week Low | $75.07 | $35.29 |
Enterprise Value | $14.67B | $241.20B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $94.12, up 3.31% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 results due July 30, 2026. Fundamentals show robust profitability with a 17.32% net margin and 63.77% gross margin, though revenue growth is moderating. Analyst consensus is bullish with a $123 price target, but legal investigations pose sentiment risks.
Outlook remains positive given earnings momentum and high analyst buy ratings, but investors face near-term volatility from legal overhangs and elevated valuation multiples. The stock offers upside to consensus targets if execution continues, yet legal and competitive pressures require monitoring for sustained growth.
Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.
Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
